Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Cleave Therapeutics

866 Malcolm, Suite 100
Burlingame, CA 94010
USA
650-443-3000
Website Company Summary Management Team
Management

CEO: Amy Burroughs (8/6/2019)
President/COO/Operations: Scott Harris (8/7/2019)
General Management: Jesse Vargas (2/28/2018)
Finance: Greg Wilson (3/31/2018)
Board

Outside board: (May no longer be on the board) Robert Garland (NEA Partner);  Andrew Schwab (5AM Ventures Managing Partner) Lewis Shuster (Shuster Capital CEO) Lawrence A. Lasky (U.S. Venture Partners) Dennis Henner (Clarus Ventures Managing Director)
Former outside board: Peter Thompson (OrbiMed Venture Partner)
Company

Business description: Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP), also known as p97, as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. The privately held company, based in San Francisco, is advancing CB-5339, its second-generation, small molecule VCP/p97 inhibitor, to clinical studies in acute myeloid leukemia (AML), while the National Cancer Institute (NCI) will sponsor and evaluate CB-5339 in clinical studies of patients with solid tumors.
Capital

Rounds: 5
Recent Fundings: Aug 2019   Aug 2016
Capital raised: 103.0M
Last Round: 12.0M
Ownership: Private  
VCs include: NEAU.S. Venture Partners5AM VenturesOrbiMedClarus Ventures;  Arcus Ventures ;  Osage University Partners
Corporate investors: Celgene

Last Tweets


 

Last Mentions


Overview
Record updated: Sep 2020
Sector: Biotech
Headcount: 11-25
Rounds: 5
Recent Fundings: Aug 2019   Aug 2016
Capital Raised: 103.0M
Last Round: 12.0M
Ownership: Private